← Back to all trials
Completed
NCT07528911
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
Conditions: Epithelial High Grade Serous Ovarian Cancer
Sex: Female
Healthy volunteers: No
Enrollment: 687
Sponsor: Hellenic Cooperative Oncology Group
Location: Hellenic Cooperative Oncology Group Athens
Summary
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Eligibility Criteria
Inclusion Criteria:
* Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy
Exclusion Criteria:
* Any other histology than high grade ovarian cancer
* Patients with stages I-II (based on FIGO staging)
Source: ClinicalTrials.gov (NCT07528911). StuddyBuddy aggregates publicly available trial information.
